Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer to Close R&D Sites | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer to Close R&D Sites

Pfizer has plans to close six R&D sites and cut an unspecified number of jobs in the U.S. and UK as part of its integration with Wyeth.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has plans to close six R&D sites and cut an unspecified number of jobs in the U.S. and the UK as part of its integration with Wyeth.

According to a company statement, Pfizer will reduce its global R&D square footage by 35%, and will discontinue R&D operations in Princeton, NJ; Chazy, Rouses Point and Plattsburgh, NY; Sanford and Research Triangle Park, NC; and Gosport, Slough/Taplow, UK.

Pfizer will now have five main R&D sites for BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, MA; Groton, CT; Pearl River, NY; La Jolla, CA; and Sandwich, U.K. These research labs will be supplemented by specialized research capabilities, such as monoclonal antibody discovery in San Francisco, regenerative medicine work in Cambridge, UK, and R&D activities in Shanghai, China.

“By focusing our R&D operations in these centers, we are building the world’s premier biopharmaceutical R&D enterprise,” said Mikael Dolsten, president of BioTherapeutics R&D. “This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients.”

While these changes are expected to bolster productivity and reduce costs, they will result in staff reductions, according to Martin Mackay, president, PharmaTherapeutics R&D.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics